

REMARKS

Claims 1-17 remain pending in the application. Claims 1-12 have been amended. Claims 13 and 14 are hereby canceled without prejudice or waiver of the right to pursue the subject matter of said claims in this or another application. New claims 15-17 have been added. Reconsideration of the pending claims is respectfully requested.

Claims 1-12 were amended to correct formal issues and place the claims in better form for allowance.

Claim 1 was amended to remove the term “alkyl” from the definition of R₁.

Claim 4 was amended to redefine the compound of formula (4) by removing the definition of the variable “n” which is not present in the formula (4).

New claim 15 was added to cover a method of enhancing colonic absorption of a glycosaminoglycan or glycosaminoglycan oligosaccharide following administration thereof. The method specifies oral or intracolonic administration of the glycosaminoglycan or glycosaminoglycan oligosaccharide and a compound according to any one of claims 1-5. Applicants submit that no new subject matter has been added. Support for the added subject matter is found in the original application as filed (pg. 1, ln. 7; pg. 2, lines 10-14; pg. 3, lines 10-15; pg. 4, line 22 to pg. 5, line 8; figures).

New claim 16 was added to cover a method of treating thrombosis, inflammation, cancer or allergy by administering to a subject in need thereof a compound according to any one of claims 1 – 4 or 5 and a glycosaminoglycan or glycosaminoglycan oligosaccharide. Applicants submit that no new subject matter has been added. Support for the added subject matter is found in the original application as filed (pg. 4, lines 18-20; Abstract).

New claim 17, which depends from and includes the subject matter of claim 16, was added to specify the mode of administration as oral, intraduodenal, intracolonic or pulmonary administration. Applicants submit that no new subject matter has been added. Support for the added subject matter is found in the original application as filed (pg. 1, lines 5-10; pg. 2, lines 10-14; pg. 3, lines 10-15; pg. 4, line 22 to pg. 5, line 8).

Claim 1 stands rejected as being anticipated by U.S. Patent No. 6,541,203 to Mitchison. The examiner indicates that FIG. 2A of Mitchison discloses a compound that is within the scope

of instant claim 1. Insofar as it may apply to the present claims, this rejection is respectfully traversed.

FIG. 2A of Mitchison depicts a compound wherein R₁ is –tert-butyl, R₂ is chloro (halo) and n is 5, said variables being defined in terms of the instant compounds. Claim 1 has been amended to delete the term “alkyl” from the definition of R₁. Therefore, claim 1 as amended is not anticipated by Mitchison.

Applicants respectfully submit that the rejection of claim 1 as being anticipated by U.S. Patent No. 6,541,203 to Mitchison has been overcome and request that it be withdrawn.

Claims 1 and 5-14 stand rejected under 35 U.S.C. 112, 2nd Para., as being indefinite for failing to particularly point out and distinctly claim the invention. Claim 1 has been rejected for use of the phrase “either alone or associated”. Claims 5-12 stand rejected for lack of antecedent basis issues. Insofar as it may apply to the present claims, this rejection is respectfully traversed.

Claim 1 has been amended to replace the phrase “either alone or associated” with the phrase “a combination thereof”, since the phrase “either alone or associated” means that the individual substituents of R₁ can each be present alone (resulting in a mono-substituted phenyl ring) or together with another substituent (resulting in a disubstituted phenyl ring). Applicants submit that no new subject matter has been added by way of this amendment as the original specification and claims clearly disclose compounds wherein the phenyl ring is substituted with one or plural R₁ functional groups.

Claims 5-12 have been amended to correct the antecedent basis issues by amending the preamble.

Applicants respectfully submit that the rejection of claims 1 and 5-14 under 35 U.S.C. 112, 2nd Para., as being indefinite for failing to particularly point out and distinctly claim the invention, has been overcome and request that it be withdrawn.

Claims 2-4 stand objected to as being dependent upon a rejected base claim. Applicants have amended claim 1 to overcome the rejection thereof. Accordingly, Applicants respectfully submit that this objection has been overcome and request that it be withdrawn.

Claim 1 stands objected to because of an informality. The claim has been amended to remove the term “alkyl” thereby rendering this objection moot. Accordingly, Applicants respectfully submit that this objection has been overcome and request that it be withdrawn.

Applicants have made a diligent effort to advance the prosecution of the application by presenting amendments to the claims and arguments in support of patentability. In view of the above, applicants submit that the claims are in form for allowance. An early notice of allowance thereof is requested.

Respectfully submitted,

Date: July 14, 2008
Innovar, L.L.C.
P.O. Box 250647
Plano, TX 75025-0647
Ph.: 972-747-7373
Fax: 972-747-7375

/RICK MATOS/
Rick Matos (Agent for Applicant)
Registration No. 40,082
Customer No. 24,039
Email: innovarllc@sbcglobal.net